Literature DB >> 25203594

The epidemiology and management of recent-onset atrial fibrillation and flutter presenting to the Emergency Department.

Ailsa Hamilton1, Donna Clark, Alasdair Gray, Aidan Cragg, Neill Grubb.   

Abstract

OBJECTIVES: Atrial fibrillation (AF) and flutter are common tachyarrhythmias seen in the Emergency Department (ED). The management of recent-onset AF remains poorly defined. Two management strategies have been proposed: rhythm control versus rate control. The aims of this study were to investigate the epidemiology and management of recent-onset AF presenting to one large tertiary ED.
METHODS: Retrospective analysis of ED records was carried out using the ED PAS database to identify eligible patients presenting between 1 July 2009 and 30 June 2011 with onset of AF in the previous 7 days. Patients were included for analysis if it was their first presentation, first diagnosis or a paroxysm of atrial fibrillation.
RESULTS: A total of 494 patients (625 presentations) were analysed. AF (n=564; 90.2%) and flutter (n=61; 9.8%) were the presenting rhythms. In all, 374 (53.8%) presentations were paroxysmal atrial fibrillation. For patients with AF, rhythm control was attempted in 171 (55.0%) patients presenting less than 48 h after symptom onset. Pharmacotherapy was the approach in 105 (31.4%) patients, compared with direct current cardioversion (n=45; 26.3%). Twenty-one patients received both. Flecainide (n=85) and amiodarone (n=33) were the main first-line pharmacotherapies, restoring sinus rhythm in 81.3 and 81.4% of patients, respectively. The overall efficacy of direct current cardioversion in restoring sinus rhythm was similar (78.8%). Eighty-one patients presented more than 48 h after symptom onset. Of those patients managed in the ED (n=38; 71.7%) were managed with rate control. The majority of patients with atrial flutter presented less than 48 h after symptom onset (n=48; 78.7%). Sixteen of these patients were managed with rhythm control strategies in the ED.
CONCLUSION: The epidemiology of recent-onset AF in this series is comparable with previous publications. Rhythm control was only attempted in approximately half of all eligible patients. There was no single-favoured management strategy. Our results mirror the literature in emphasizing the variation in management and the lack of robust evidence guiding the management of recent-onset AF and flutter.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25203594     DOI: 10.1097/MEJ.0000000000000198

Source DB:  PubMed          Journal:  Eur J Emerg Med        ISSN: 0969-9546            Impact factor:   2.799


  6 in total

1.  A randomized, controlled comparison of electrical versus pharmacological cardioversion for emergency department patients with acute atrial flutter.

Authors:  Ian G Stiell; Marco L A Sivilotti; Monica Taljaard; David Birnie; Alain Vadeboncoeur; Corinne M Hohl; Andrew D McRae; Judy Morris; Eric Mercier; Laurent Macle; Robert J Brison; Venkatesh Thiruganasambandamoorthy; Brian H Rowe; Bjug Borgundvaag; Catherine M Clement; Jennifer Brinkhurst; Erica Brown; Marie-Joe Nemnom; George A Wells; Jeffrey J Perry
Journal:  CJEM       Date:  2021-01-18       Impact factor: 2.410

2.  From Bench to Bedside-Implementing the New ABC Approach for Atrial Fibrillation in an Emergency Department Setting.

Authors:  Sophie Gupta; Martin Lutnik; Jan Niederdöckl; Sebastian Schnaubelt
Journal:  Int J Environ Res Public Health       Date:  2022-04-15       Impact factor: 4.614

3.  Predictors of time to conversion of new-onset atrial fibrillation to sinus rhythm with amiodarone therapy.

Authors:  Ihsan Dursun; Sinan Sahin; Ali Bayraktar; Omer Faruk Cirakoglu; Selim Kul; Levent Korkmaz
Journal:  J Arrhythm       Date:  2020-06-01

4.  Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs.

Authors:  Antonio Bonora; Gianni Turcato; Elena Franchi; Gabriele Taioli; Alice Dilda; Germana Zerman; Antonio Maccagnani; Claudio Pistorelli; Oliviero Olivieri
Journal:  Intern Emerg Med       Date:  2016-07-06       Impact factor: 3.397

5.  Effect of Early Pharmacologic Cardioversion vs. Non-early Cardioversion in the Patients With Recent-Onset Atrial Fibrillation Within 4-Week Follow-Up Period: A Systematic Review and Network Meta-Analysis.

Authors:  Yan Tang; Yujie Wang; Xuejing Sun; Yunmin Shi; Suzhen Liu; Weihong Jiang; Hong Yuan; Yao Lu; Jingjing Cai; Junru Wu
Journal:  Front Cardiovasc Med       Date:  2022-04-11

6.  Pharmacological Cardioversion With Antazoline in Atrial Fibrillation: The Results of the CANT Study.

Authors:  Maciej T Wybraniec; Wojciech Wróbel; Katarzyna Wilkosz; Karolina Wrona; Karolina Bula; Katarzyna Mizia-Stec
Journal:  J Am Heart Assoc       Date:  2018-10-16       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.